OPKO Health, Inc.-Product Pipeline Review-2015

OPKO Health, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07247CDB
  • |
  • Pages: 75
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

OPKO Health, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'OPKO Health, Inc.-Product Pipeline Review-2015', provides an overview of the OPKO Health, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OPKO Health, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of OPKO Health, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of OPKO Health, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the OPKO Health, Inc.'s pipeline products

Reasons To Buy

Evaluate OPKO Health, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of OPKO Health, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the OPKO Health, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of OPKO Health, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of OPKO Health, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of OPKO Health, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

OPKO Health, Inc. Snapshot 7

OPKO Health, Inc. Overview 7

Key Information 7

Key Facts 7

OPKO Health, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

OPKO Health, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

OPKO Health, Inc.-Pipeline Products Glance 15

OPKO Health, Inc.-Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

OPKO Health, Inc.-Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

OPKO Health, Inc.-Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

OPKO Health, Inc.-Drug Profiles 21

calcifediol 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

fermagate 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

MOD-4023 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

CTAP-201 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

lunacalcipol 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

MOD-5014 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

OPK-0018 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

CTA-091 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Cancer 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

influenza vaccine 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

MOD-1001 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

MOD-1002 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

MOD-6030 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

MOD-6031 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

MOD-7023 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

MOD-9013 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

MOD-9017 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Oligonucleotide for Dravet Syndrome 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Oligonucleotide for Mucopolysaccharidosis I 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Oligonucleotide for Rett Syndrome 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

SR-3306 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Protein for Atherosclerosis 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Protein for Rheumatoid Arthritis 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

OPKO Health, Inc.-Pipeline Analysis 49

OPKO Health, Inc.-Pipeline Products by Target 49

OPKO Health, Inc.-Pipeline Products by Route of Administration 51

OPKO Health, Inc.-Pipeline Products by Molecule Type 52

OPKO Health, Inc.-Pipeline Products by Mechanism of Action 53

OPKO Health, Inc.-Recent Pipeline Updates 54

OPKO Health, Inc.-Dormant Projects 67

OPKO Health, Inc.-Company Statement 68

OPKO Health, Inc.-Locations And Subsidiaries 72

Head Office 72

Other Locations & Subsidiaries 72

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

OPKO Health, Inc., Key Information 7

OPKO Health, Inc., Key Facts 7

OPKO Health, Inc.-Pipeline by Indication, 2015 9

OPKO Health, Inc.-Pipeline by Stage of Development, 2015 11

OPKO Health, Inc.-Monotherapy Products in Pipeline, 2015 12

OPKO Health, Inc.-Out-Licensed Products in Pipeline, 2015 13

OPKO Health, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 14

OPKO Health, Inc.-Pre-Registration, 2015 15

OPKO Health, Inc.-Phase III, 2015 16

OPKO Health, Inc.-Phase II, 2015 17

OPKO Health, Inc.-Phase I, 2015 18

OPKO Health, Inc.-Preclinical, 2015 19

OPKO Health, Inc.-Discovery, 2015 20

OPKO Health, Inc.-Pipeline by Target, 2015 50

OPKO Health, Inc.-Pipeline by Route of Administration, 2015 51

OPKO Health, Inc.-Pipeline by Molecule Type, 2015 52

OPKO Health, Inc.-Pipeline Products by Mechanism of Action, 2015 53

OPKO Health, Inc.-Recent Pipeline Updates, 2015 54

OPKO Health, Inc.-Dormant Developmental Projects,2015 67

OPKO Health, Inc., Subsidiaries 72

List of Figures

OPKO Health, Inc.-Pipeline by Top 10 Indication, 2015 9

OPKO Health, Inc.-Pipeline by Stage of Development, 2015 11

OPKO Health, Inc.-Monotherapy Products in Pipeline, 2015 12

OPKO Health, Inc.-Out-Licensed Products in Pipeline, 2015 13

OPKO Health, Inc.-Pipeline by Top 10 Target, 2015 49

OPKO Health, Inc.-Pipeline by Top 10 Route of Administration, 2015 51

OPKO Health, Inc.-Pipeline by Top 10 Molecule Type, 2015 52

OPKO Health, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of OPKO Health, Inc.; OPKO Health, Inc. - Key Therapeutics; OPKO Health, Inc. - Pipeline Overview and Promising Molecules; OPKO Health, Inc. - News; OPKO Health, Inc. - Latest Updates; OPKO Health, Inc. - Pipeline; OPKO Health, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102135
Site License
USD 3000 INR 204270
Corporate User License
USD 4500 INR 306405



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com